MS-based proteomics can be broadly grouped into top-down proteomics, in which intact proteins are measured, and bottomup proteomics, in which peptides are measured as surrogates for the protein of interest; in this Perspective, we focus on bottom-up proteomics. The typical bottom-up proteomics workflow starts In this Perspective, we discuss developments in mass-spectrometry-based proteomic technology over the past decade from the viewpoint of our laboratory. We also reflect on existing challenges and limitations, and explore the current and future roles of quantitative proteomics in molecular systems biology, clinical research and personalized medicine.
with trypsin digestion of a protein sample into short peptides, which are then separated by liquid chromatography, either directly or after biochemical fractionation 3 (Fig. 1a) . As peptides elute from the chromatography column, they are subjected to electrospray ionization 4, 5 and are directly sprayed into the mass spectrometer, where two levels of MS measurement take place in tandem 3 . At the first level, a mass analyzer measures the mass-to-charge ratio (m/z) of peptide molecular ions (MS1). At the second level, m/z values of fragment ions resulting from the fragmentation of specific peptide ions are detected (MS2). The specific fragment ion pattern of each peptide ion, together with its m/z value, enables the confident identification of peptides present in the sample. The identified peptide sequences can then be mapped to proteins, and the signal intensities of either peptides or fragment ions can be used to estimate relative changes in abundance across samples.
In the mid-1990s, to account for technical variability at various stages of sample handling and during measurements, we and others started to develop strategies based on isotopic labeling 6, 7 , including chemical isotopic labeling 8 , metabolic isotopic labeling 9 and isobaric tagging 10, 11 . Another important application of isotopic labeling in MS is the use of labeled spike-in peptides or proteins of known concentration that enable the determination of absolute concentrations of proteins in a sample, for example, in terms of the number of molecules per cell or nanograms per milliliter of blood 12 . Although label-based approaches are still the gold standard for quantification by MS-based proteomics methods 13 , in recent years label-free approaches have become more popular thanks to their simpler experimental designs and sample-preparation methods 6, 14 . Among the developments driving this transition are the advance of commercially available high-resolution and fast-scanning instruments, such as the Orbitrap (2005) 15 , and continuous improvement of time-of-flight mass spectrometers 16 , combined with improvements in software for the alignment of multiple MS runs 17, 18 . Another, more recent trend that started in 2006 19 is label-free absolute quantification, in which the absolute concentrations of all proteins measured in a sample are estimated on the basis of summarized ion counts.
Proteins constitute a large part of the molecular machinery of the cell and are the major class of biomolecules targeted by drugs. Organized in functional modules and networks, they carry out cellular functions and determine phenotypes by means of coordinated activities of a multitude of molecular species 1 . Traditional biochemical methods for studying proteins have been highly biased toward a relatively small subset of proteins for which high-quality, mainly antibody-based assays have been available 2 . Over the past two decades, mass spectrometry (MS)-based methods have emerged as the method of choice for the confident and near-exhaustive identification and quantification of the proteins contained in a biological sample, and have significantly contributed to the unraveling of cellular signaling networks, elucidation of the dynamics of proteinprotein interactions in different cellular states, and improved diagnosis and molecular understanding of disease mechanisms. Overall, MS-based proteomics can reveal the quantitative state of a proteome, and thereby provides insights into the biochemical state of the relevant cell or tissue. In the following paragraphs, we discuss important concepts and developments in proteomics technology and explore the current and future roles of quantitative proteomics in molecular systems biology as well as in clinical research and personalized medicine. (Fig. 1b) . The strength of discovery proteomics (also known as shotgun proteomics, and exemplified by data-dependent acquisition) arises from its capability to identify thousands of proteins per run. However, with complex samples, researchers have often faced limitations regarding the repeatability of peptide identification and the consistency of quantification 24, 25 . Recent developments in chromatographic performance and These counts can then be converted into a meaningful unit through comparison to the total amount of protein injected into the mass spectrometer, or by correlation to a set of spiked-in reference peptides of known concentration [20] [21] [22] [23] .
Regardless of whether label-based or label-free strategies are used, bottom-up proteomics methods have traditionally been divided into discovery proteomics and targeted proteomics Although the most widely used untargeted approach (also referred to as shotgun or data-dependent acquisition) is relatively simple and can be applied to any sample without prior knowledge, the data obtained can have missing data points as a result of the stochastic sampling process. In contrast, targeted acquisition acquires peptide and fragment ion data in a highly consistent manner, thus allowing accurate and sensitive quantification, but it is limited to a relatively small, predefined set of peptides. Data-independent acquisition (DIA) acquires data from all detectable fragment ions in a sample in a systematic and consistent manner, but because of the relatively large peptide-ion isolation windows (m/z dimension), the resulting data are more complex than those obtained with the other two acquisition schemes. (c) DIA data can be analyzed in different ways-by either direct analysis of the multiplexed MS2 spectra or initial extraction of a subset of informative fragment ion signals (this step requires prior knowledge) that are then used to derive quantitative data for specific peptides 36, 40 .
proteomics 24, 52 and targeted proteomics 53 . In a recent study using DIA/SWATH-type methods 54,55 , we found that over 4,000 proteins from more than 200 measurements of a human cell line could be independently identified and quantified across laboratories and instruments with coefficients of variation typically around 20% (ref. 54 ). These results show that quantitative proteomics has matured and is capable of delivering accurate, reproducible and comprehensive data at high throughput.
In the following two sections, we briefly outline our view of the field's current and future roles in molecular systems biology as well as in clinical research and applications.
Quantitative proteomics in molecular systems biology and the study of cellular organization
The comprehensive quantification of proteins, in addition to their post-translational modification status across conditions or over time in response to a stimulus or perturbation, is an important aspect of systems biology studies. Thanks to the technological advances described above, the quality of the resulting quantitative data matrices for large numbers of samples has substantially improved over time, enabling us and others to conduct systemsoriented studies involving not only microorganisms but also higher organisms, including mammals 23, 47, 50, 56, 57 .
Proteins are not isolated molecules but three-dimensional objects acting in the context of other proteins; their modular and spatial organization can therefore be as important as their expression levels 1, 58 . MS-based proteomics methods developed to query the organizational units of the proteome typically combine MS measurements with biochemical assays (Fig. 2) . The oldest of these methods, first described in 1999 (ref. 59) , is affinity purification coupled to MS to identify interaction partners of a specific protein [60] [61] [62] . More recently, proteome fractionation using native separations has been applied to study the protein complexes in a cell on a proteome-wide scale [63] [64] [65] . To determine the subunit topologies of protein complexes and thereby obtain insights into the architecture of macromolecular assemblies, we and others have used approaches based on chemical cross-linking of protein residues [66] [67] [68] ; the addition of a quantitative dimension enables one to probe dynamic changes in protein complex composition and structure 69, 70 . Furthermore, the spatial resolution of the proteome within a cell can be investigated via the combination of proteomic techniques with enzymatic activities to label proximate or interacting proteins of a particular protein of interest 71 . Overall, these techniques highlight the power and flexibility of MS-based proteomics to produce not only a comprehensive and highquality data matrix of protein abundances across a large number of samples, but also a dynamic, three-dimensional view of the proteome and its modular and spatial organization, both of which are critical to a full understanding of complex biological systems.
Quantitative proteomics in molecular medicine
One of the major challenges in clinical studies is the requirement for large patient cohorts to compensate for the biological and experimental variability among clinical samples. In contrast to genomics, proteomics analyses of cohorts consisting of hundreds MS hardware have alleviated some of these concerns and allow high-quality quantitative measurement of near-complete proteomes, even in very complex samples such as human cell lines and tissues [26] [27] [28] [29] .
About a decade ago, to overcome the limited scalability and reproducibility of discovery proteomics in studies designed to quantify proteins in cohorts consisting of large numbers of samples, we and others started exploring the capabilities of targeted proteomics (exemplified by selected/multiple reaction monitoring 30, 31 and, more recently, parallel reaction monitoring 32, 33 ). Targeting methods provide consistent and accurate quantification, even at low abundances and in complex mixtures. Although targeted proteomics is typically limited to a few dozen predefined proteins per run, its sensitivity and quantitative capabilities make it well suited for hypothesis-driven research and clinical studies in which a small number of proteins, such as potential biomarkers, are to be measured in a large number of patient samples 34 .
A third type of MS acquisition, falling between the two wellestablished techniques described above, has gained remarkable momentum in the past five years: data-independent acquisition (DIA) 35, 36 . In this method, multiplexed fragment ion spectra are acquired systematically through the use of deterministic peptideion isolation windows that collectively span the mass range in which most tryptic peptides are expected to be located (Fig. 1b) . DIA was first described in the early 2000s 37, 38 , and in subsequent years various further implementations and developments of the concept were reported 35, 36 . Although these methods were of substantial conceptual interest and also led to a commercial implementation referred to as MS E (ref. 39) , their adoption in the field was somewhat limited owing to the overwhelmingly multiplexed data that resulted from their application to high-complexity samples. In 2012, our lab described a new DIA-based method termed SWATH-MS, which uses a targeted paradigm for the analysis of DIA data 40 . This novel analysis strategy based on comprehensive spectral libraries 41 and refined targeted scoring algorithms 42 , together with improved instrumentation and an optimized acquisition scheme, enabled us to efficiently deconvolute highly multiplexed DIA data and use them to achieve highly consistent quantification of thousands of analytes (Fig. 1c) . The latest developments in DIA methods include coupling with ion mobility 43 , new acquisition schemes 44 , and new data analysis modes and software tools 45, 46 . Combining the analyte throughput of discovery proteomics with the accuracy and repeatability of targeted proteomics methods enables DIA/SWATH-type techniques to be applied successfully in a variety of studies, and they are becoming increasingly prevalent in the quantitative proteomics field, particularly in studies that require the consistent analysis of large sample cohorts 23, [47] [48] [49] [50] .
Over the years, the sensitivity and speed of mass spectrometers have improved at a rapid pace; however, obtaining robust, quantitative data across large numbers of samples remains one of the greatest challenges in proteomics, even for expert labs 51 . The most rigorous way to assess the capabilities and pitfalls of proteomics methods is the use of interlaboratory comparison studies. Such studies have been conducted for both discovery measurements of specific protein and metabolite levels are used to evaluate an individual's health status and to prevent the development of disease in a timely manner through dietary, exercise-based or drug-based interventions 75 (Fig. 3) . Although immunoassays are the traditional way to measure protein biomarkers, targeted proteomics techniques offer a number of advantages, including faster assay development, multiplexing capabilities and analytical specificity, and are therefore the method of choice to test panels of candidate biomarkers before they enter clinical validation studies [76] [77] [78] .
Conclusion
Over the past two decades, we have witnessed rapid developments in MS instrumentation, as well as in acquisition methods and analysis strategies. Furthermore, quantitative proteomics has contributed enormously to biological and clinically oriented research. However, current approaches to instrument operation, data acquisition and analysis still require highly specialized expertise. Many facilities, including ours, are therefore working toward the development of more robust MS-based methods and automated analysis pipelines to make quantitative proteomics available not just to expert labs, but also to general molecular biology laboratories in academia, hospitals and industry. of samples are still prohibitively time-consuming and expensive, especially if large numbers of proteins are to be quantified consistently across the cohort. Two remarkable studies from 2016 used discovery proteomics to quantify several thousand proteins across over 100 patient samples each; both efforts required several months of instrument time 72, 73 . To conduct studies at a larger scale, proteomics techniques that allow higher throughput while maintaining robustness, repeatability and sensitivity are therefore essential. DIA/SWATH-type approaches have emerged as a promising alternative for the quantitative proteomic analysis of clinical samples, and early studies applied them successfully to quantify large numbers of proteins across hundreds of human patient samples 74 .
Scientists can use the data sets generated from such studies to uncover cellular mechanisms and processes that are affected in the disease under study. Alternatively, quantitative proteomics techniques can be used to profile potential protein biomarkers in patient tissue, blood or urine to inform disease risk, diagnosis, prognosis and treatment stratification (Fig. 3) . Biomarkers also have a crucial role in the emerging field of personalized medicine, in which recurrent molecular Figure 2 | A selection of methods used to explore the modular and spatial organization of the proteome. Two methods for the study of protein-protein interactions and protein complexes as they occur within a cell are affinity purification and protein correlation profiling. For both methods, cells are lysed under native conditions to preserve proteinprotein interactions. For affinity purification, a protein of interest is purified either via an affinity tag genetically added to the protein or with a specific antibody, and is then subjected to MS analysis to identify proteins that directly or indirectly bind to it 60 . For protein correlation profiling, a cell lysate is fractionated-for example, by size-exclusion chromatography-and after MS analysis of all the resulting fractions, correlation analysis is carried out to identify coeluting proteins, which are likely to have been part of the same protein complex [63] [64] [65] . Chemical cross-linking can be used to gain insights into the topology of a protein complex [66] [67] [68] . After the digestion of cross-linked proteins, cross-linked peptides can be identified by MS, and provide information on which parts of which proteins are in close proximity within the protein complex. Another emerging method is proximity labeling (also called BioID), which uses a ubiquitous biotin ligase fused to a protein of interest to biotinylate all proteins in its proximity 71 . Biotinylated proteins can then be isolated and identified by MS. The BioID method captures not only stable protein complexes but also transient interactions between proteins that could not be captured by the other methods mentioned here. Longitudinal profiling of individuals allows the molecular profile of a person to be monitored over long time frames, and comparison of each measurement with data for the same subject from previous time points yields more meaningful clinical information than comparison of a single measurement with the population average. This personalized approach to molecular medicine is expected to enable early and highly sensitive detection of disease risk, and is therefore most effective in disease prevention. 
